Drug name - Vosevi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9585906 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(8 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US9868745 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(10 years from now)

US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(11 years from now)

CN102906102A GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus-Containing Active Matter
Nov, 2015

(6 years ago)

CN104244947A GILEAD SCIENCES INC Methods And Compositions For Treating Hepatitis C Virus
Aug, 2016

(6 years ago)

CN104292256A GILEAD SCIENCES INC N - [(2 ' R) -2 '--2 '--2 ' - Methyl-Beta-Phenyl - -5 ' - Uridine Acyl] -L - Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof
Nov, 2018

(3 years ago)

CN105198949A GILEAD SCIENCES INC N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Its Preparation Method
Dec, 2019

(2 years ago)

CN106166160A GILEAD SCIENCES INC Composition For Treating Hcv
Oct, 2021

(1 year, 3 days ago)

CN102459299B GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' -Fluoro-2 ' -Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine 1-Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

CN105085592A GILEAD SCIENCES INC N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof
May, 2030

(7 years from now)

CN102459299A GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' - Fluoro-2'-Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine-1-Methylethyl Ester Process For Its Production
May, 2030

(7 years from now)

CN105085592B GILEAD SCIENCES INC N - [(2 ' R) - 2 ' - Deoxy-2 ' - Fluorine-2 ' - Methyl-Beta-Phenyl-5 ' - Uridine Acyl] -L - Lactamine 1-Methyl Ethyl Ester And Its Preparation Method
May, 2030

(7 years from now)

CN104017020A GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

CN104017020B GILEAD SCIENCES INC Nucleoside Phosphoramidate
Mar, 2031

(8 years from now)

CN104244945A GILEAD SCIENCES INC Methods For Treating Hcv
Sep, 2032

(9 years from now)

CN104039319B GILEAD SCIENCES INC Composition And Method For Treating Hcv
Sep, 2032

(9 years from now)

CN104039319A GILEAD SCIENCES INC Methods And Compositions For Treating Hepatitis C Virus
Sep, 2032

(9 years from now)

CN104244945B GILEAD SCIENCES INC Methods For Treating Hcv
Sep, 2032

(9 years from now)

CN103328480A GILEAD SCIENCES INC A Imidazole Imidazole For Condensation Of Antiviral Composition
Nov, 2032

(10 years from now)

CN105837584A GILEAD SCIENCES INC Condensed Imidazolyl-Imidazole As Antiviral Compound
Nov, 2032

(10 years from now)

CN105837584B GILEAD SCIENCES INC Condensation Of Imidazole Imidazole As Antivirus Compound
Nov, 2032

(10 years from now)

CN103328480B GILEAD SCIENCES INC Condensed Imidazolyl-Imidazole As Antiviral Compound
Nov, 2032

(10 years from now)

CN103663345B GILEAD SCIENCES INC Microelectromechanical System (Mems) Device And Fabrication Method Thereof
Jan, 2033

(10 years from now)

CN103663345A GILEAD SCIENCES INC Microelectromechanical System (Mems) Device And Fabrication Method Thereof
Jan, 2033

(10 years from now)

CN106117309B GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

CN104540832B GILEAD SCIENCES INC Type Iii Hepatitis Virus Inhibitor
Jul, 2033

(10 years from now)

CN104540832A GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

CN106117309A GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

IN346815B GILEAD SCIENCES INC N-[ (2&Amp;Apos;R) -2&Amp;Apos; Deoxy-2&Amp;Apos;- Fluoro-2&Amp;Apos;-Methyl-Pphenyl- 5&Amp;Apos;-Uridylyl] -L-Alanine 1- Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

IN310576B GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

IN201402598P3 GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

EP2203462B1 GILEAD SCIENCES INC Nucleoside Phosphoramidate Prodrugs
Jul, 2020

(2 years ago)

EP2203462A2 GILEAD SCIENCES INC Nucleoside Phosphoramidate Prodrugs
Jul, 2020

(2 years ago)

EP2826784B1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP2826784A1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP2913337A1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792A1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

EP3321275B1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP3321275A1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792B1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

EP2913337B1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP2752422A1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP3290428B1 GILEAD SCIENCES INC Tablet Comprising Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1 (2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552930B1 GILEAD SCIENCES INC Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1-(2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552931A2 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP2552931B1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP2609923A2 GILEAD SCIENCES INC Process For The Crystallisation Of (S)-Isopropyl 2-(((S)-(Perfluorophenoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552930A2 GILEAD SCIENCES INC Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1-(2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2609923A3 GILEAD SCIENCES INC Nucleoside Phosphoramidates
Mar, 2031

(8 years from now)

EP3290428A1 GILEAD SCIENCES INC Tablet Comprising Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1 (2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2752422B1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP2609923B1 GILEAD SCIENCES INC Process For The Crystallisation Of (S)-Isopropyl 2-(((S)-(Perfluorophenoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2640719B1 GILEAD SCIENCES INC Antiviral Compounds
Nov, 2031

(9 years from now)

EP2640719A2 GILEAD SCIENCES INC Antiviral Compounds
Nov, 2031

(9 years from now)

EP2709613A2 GILEAD SCIENCES INC Methods For Treating Hcv
Sep, 2032

(9 years from now)

EP2709613B2 GILEAD SCIENCES INC Methods For Treating Hcv
Sep, 2032

(9 years from now)

EP2709613B1 GILEAD SCIENCES INC Methods For Treating Hcv
Sep, 2032

(9 years from now)

EP3431477A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2635588A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2907816A1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP3431477B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2907816B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2635588B1 GILEAD SCIENCES INC Condensed Imidazolylimidazoles As Antiviral Compounds
Nov, 2032

(10 years from now)

EP2785340A1 GILEAD SCIENCES INC Compositions And Methods For Treating Hepatitis C Virus
Nov, 2032

(10 years from now)

EP2785340B1 GILEAD SCIENCES INC Compositions And Methods For Treating Hepatitis C Virus
Nov, 2032

(10 years from now)

EP3159345A1 GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

EP3492464B1 GILEAD SCIENCES INC Intermediates For Preparing Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

EP3492464A1 GILEAD SCIENCES INC Intermediates For Preparing Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

EP2870160A1 GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

EP2870160B1 GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

EP3159345B1 GILEAD SCIENCES INC Inhibitors Of Hepatitis C Virus
Jul, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957046 GILEAD SCIENCES INC NA Mar, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Jun, 2031

(8 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jan, 2034

(11 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds Jul, 2034

(11 years from now)

US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds Jun, 2037

(14 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
400MG;100MG;100MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.